US Pharma MarketingIn latest twist in Zepzelca saga, Jazz and PharmaMar lung cancer drug fails phase 3 test
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer (SCLC) drug Zepzelca may once again be in jeopardy. The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.
The accelerated approval for Jazz Pharmaceuticals’ small cell lung cancer drug Zepzelca may once again be in jeopardy after another phase 3 failure.
Source: FiercePharma